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D-amino acid oxidase (DAO, DAAO) degrades the NMDA receptor co-agonist D-serine,
modulating D-serine levels and thence NMDA receptor function. DAO inhibitors are
under development as a therapy for schizophrenia, a disorder involving both NMDA
receptor and dopaminergic dysfunction. However, a direct role for DAO in dopamine
regulation has not been demonstrated. Here, we address this question in two ways.
First, using in situ hybridization and immunohistochemistry, we show that DAO mRNA
and immunoreactivity are present in the ventral tegmental area (VTA) of the rat, in
tyrosine hydroxylase (TH)-positive and -negative neurons, and in glial fibrillary acidic
protein (GFAP)-immunoreactive astrocytes. Second, we show that injection into the VTA
of sodium benzoate, a DAO inhibitor, increases frontal cortex extracellular dopamine, as
measured by in vivo microdialysis and high performance liquid chromatography. Combining
sodium benzoate and D-serine did not enhance this effect, and injection of D-serine alone
affected dopamine metabolites but not dopamine. These data show that DAO is expressed
in the VTA, and suggest that it impacts on the mesocortical dopamine system. The
mechanism by which the observed effects occur, and the implications of these findings
for schizophrenia therapy, require further study.
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INTRODUCTION
D-amino acid oxidase (DAO, DAAO; EC 1.4.3.3) is an enzyme
which oxidatively deaminates neutral D-amino acids, including
those derived from food and intestinal flora (Pollegioni et al.,
2007). Its relevance for neurobiology emerged when one of its
substrates, D-serine, was shown to be synthesized endogenously
in brain, and to be a major co-agonist at the NMDA receptor
(Schell et al., 1995; Wolosker et al., 1999; Mothet et al., 2000).
Subsequent work has highlighted the roles of D-serine and its
importance for brain function and dysfunction (Schell et al.,
1997; Stevens et al., 2003; Yang et al., 2003; Shleper et al., 2005;
Panatier et al., 2006; Strick et al., 2011; Fossat et al., 2012; Papouin
et al., 2012; Gustafson et al., 2013; for review, see Wolosker et al.,
2008; Oliet and Mothet, 2009; Van Horn et al., 2013), and it has
become clear that DAO activity is a determinant of D-serine levels
(Almond et al., 2006; Adage et al., 2008; Duplantier et al., 2009;
Strick et al., 2011).
Interest has grown in the role of DAO in several neuropsy-
chiatric disorders, especially schizophrenia, a disorder in which
NMDA receptor-related hypofunction is pathophysiologically
implicated (Javitt and Zukin, 1991; Olney et al., 1999; Tsai and
Coyle, 2002; Kantrowitz and Javitt, 2010; Marek et al., 2010;
Coyle, 2012) and is a target of much therapeutic research (Krystal
et al., 2010; Moghaddam and Javitt, 2012). Evidence that DAO
contributes to the glutamatergic dysfunction in schizophrenia is
threefold (Verrall et al., 2010; Labrie et al., 2012; Sacchi et al.,
2013): it may be a susceptibility gene (Chumakov et al., 2002;
Allen et al., 2008; Shi et al., 2008; Sun et al., 2008); DAO expres-
sion and activity are increased (Kapoor et al., 2006; Verrall et al.,
2007; Burnet et al., 2008a; Madeira et al., 2008); and DAO
inhibitors show preliminary preclinical (Adage et al., 2008) and
clinical (Lane et al., 2013) evidence for therapeutic efficacy.
DAO is conventionally viewed as a hindbrain enzyme, with
little evidence for functionality in other brain regions (Horiike
et al., 1994). This is a puzzle with regard to schizophrenia,
which is primarily a disorder of the cerebral cortex, and one
in which aberrant dopaminergic function plays a key role in
pathophysiology (Howes and Kapur, 2009; Laruelle, 2013) and
treatment (Kapur and Mamo, 2003). To date, little is known
about whether and how DAO impacts on the dopamine system.
Moreno et al. (1999) reported DAO immunoreactivity in neu-
rons and glia of the rat substantia nigra and ventral tegmental
area (VTA), and Verrall et al. (2007) found initial evidence for
DAO immunoreactivity in neurons of human substantia nigra.
Fernandez-Espejo et al. (2008) showed that injection of the proto-
typical DAO inhibitor sodium benzoate (Klein and Kamin, 1941;
van den Berghe-Snorek and Stankovich, 1985) into the rat VTA
affected cocaine sensitization (a dopamine-mediated behavior),
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but no neurochemical characterization was reported. Finally,
ddY/DAO− mice, which express inactive DAO due to a point
mutation in the gene (Gly181Arg), show differential responses
to amphetamine compared to wild-type mice (Hashimoto et al.,
2008). Despite these studies, neither the presence of DAO in the
VTA, nor an effect of DAO on dopamine neurons, has yet been
clearly established.
The present study had two objectives. First, to determine
whether or not DAOmRNA and immunoreactivity are present in
the rat VTA, using in situ hybridization and immunohistochem-
istry. Second, to assess whether VTA DAO impacts on the meso-
cortical dopamine projection, by measuring cortical dopamine
using in vivo microdialysis after acute inhibition of VTA DAO
with sodium benzoate. In addition, since the effects of DAO inhi-
bition are often assumed to be exerted via the resulting elevation
of D-serine availability, the effects on cortical dopamine of intra-
VTA injection of D-serine were also studied, with or without
sodium benzoate. Our results show that DAOmRNA and protein
are present in the VTA, in neurons and glia, and that intra-VTA
injection of a DAO inhibitor acutely increases levels of corti-
cal dopamine and its metabolites. However, the effect does not
appear to be mediated entirely via D-serine, and the mechanism
remains unclear.
MATERIALS AND METHODS
IN SITU HYBRIDIZATION HISTOCHEMISTRY
To detect and localize DAO mRNA in the VTA, we used in situ
hybridization histochemistry. 10–15 coronal sections (14µm)
through the VTA, or cerebellum (used as a positive control),
were cut on a cryostat from four fresh frozen adult Sprague-
Dawley rat brains, collected onto polylysine-coated slides and
stored at −80◦C. Before use, sections were fixed in 4% formalde-
hyde (in diethylpyrocarbonate [DEPC]-treated PBS) before being
treated with DEPC-treated triethanolamine containing 0.25%
acetic anhydride, dehydrated in graded ethanols and chloroform
(5min each), rehydrated to 95% ethanol and air-dried.
DAO cDNA was amplified from rat cerebellar cDNA
using forward and reverse primers (forward sequence:
GTGATGCGCGTGGCCGTGAT; reverse sequence: GGAATAC
ACCTCCGAGTGTA), purified and ligated into pGEM-T Easy
Vector. Plasmids were transformed into E. Coli, grown up
overnight and positive colonies selected using blue-white reagent.
Plasmids were extracted and purified using ChargeSwitch®-Pro
Plasmid Miniprep Kit and eluted with 50µl elution buffer. 10µg
plasmid was then digested with either SacII or PstI to linearize
the construct.
To create the riboprobe, approximately 1µg of linearized plas-
mid was dried down with [35S]UTP and then incubated with
NTPs, RNAsin, reaction buffer, dithiothreitol (DTT) and either
SP6 or T7 RNA polymerase to transcribe the SacII and PstI
linearized constructs, producing sense, or antisense sequences,
respectively. The plasmid DNA template was then removed using
DNase. The probe was hydrolyzed by adding hydrolysis buffer
and tRNA and incubating at 60◦C for 34min. The hydrolyzed
probe was purified using NICK columns (GE Healthcare). The
probe was diluted to 1.2 × 104cpm/µl in hybridization buffer
containing DTT and 200µl added to each section. Sections were
cover-slipped and incubated overnight at 45◦C in trays pre-
pared with filter paper soaked in 4× saline-sodium citrate buffer
(SSC) containing 50% formamide. Sections were rinsed twice
in 2× SSC at room temperature before sequential stringency
washes were carried out to remove adventitiously bound probe:
RNase A buffer, 30min at room temperature; 2× SSC, 10min at
55◦C; 0.5× SSC, 10min at 55◦C; 0.1× SSC, 3 × 20min at 55◦C;
0.1× SSC, 45min at room temperature. Sections were rinsed in
dH20, dipped in autoradiography emulsion (Amersham, UK),
and exposed for 2 months at 4◦C. Sections were developed,
counterstained using cresyl violet, and cover-slipped.
NORTHERN BLOTTING
The DAO riboprobe was verified by northern blotting, performed
using standard methods. Briefly, total cellular RNA (20µg) was
prepared from cerebellum using the Tri-reagent (Sigma-Aldrich,
UK), denatured and electrophoresed through 1.2% formamide-
agarose gels and transferred to a nylon membrane. The mem-
brane was pre-hybridized for 1 h at 42◦C in hybridization buffer
(5× saline-sodium citrate (SSC), 5× Denhardt’s solution, 1%
sodium dodecyl sulfate (SDS), 50% formamide, and 100µg/ml
of denatured salmon sperm DNA). The full length rat DAO open
reading frame (1042 bp) was labeled with [32P]-CTP using ran-
dom primers and the Klenow fragment of DNA polymerase I. The
cDNA probe was purified, denatured at 95◦C, and mixed with
fresh hybridization buffer. This was incubated with the mem-
brane overnight at 42◦C. The membrane was then washed in 2×
SSC (10min), 0.5× SSC (10min), and twice in 0.1× SSC (30min)
at 55◦C. All solutions contained 0.1% SDS. The membrane was
exposed to Kodak XAR-5 film at−70◦Cwith intensifying screens.
IMMUNOFLUORESCENCE
To investigate whether DAO protein as well as DAO
mRNA is expressed in VTA, we used immunofluorescence
with an anti-DAO antibody. The antibody was a rabbit
polyclonal, directed against a C-terminal peptide sequence
(H-CGRILEEKKLSRMPPSHL-OH; N-terminal Cys added for
coupling); the antibody has been validated by western blotting
in rat brain previously (Verrall et al., 2007) and staining is
abolished in DAO knockout mice (Schweimer et al., in review).
We co-immunostained sections for tyrosine hydroxylase (TH) to
identify VTA dopaminergic neurons, and for glial fibrillary acidic
protein (GFAP) to label astrocytes.
Adult Sprague-Dawley rats (n = 3) were perfused using 4%
paraformaldehyde and the brains removed and cryoprotected in
sucrose solution. 20µm sections containing VTA or cerebellum
were cut using a cryostat, washed in PBS, then incubated in
50mM ammonium chloride for 10min. Further washing was car-
ried out once in PBS, and twice in PBS containing Triton X-100 at
0.2% (PBSX), before blocking for 1 h in 6% normal donkey serum
in PBSX. VTA sections (n = 6 per rat) were incubated overnight
at 4◦C with the anti-DAO antibody at 1:500 in 2% normal don-
key serum in PBSX, with chicken primary anti-TH antibody
(Abcam ab76422) at 1:1000 and goat primary anti-GFAP anti-
body (Abcam ab53554) at 1:2000. Following washes in PBS, VTA
sections were soaked for 1 h in secondary donkey anti-rabbit
IgG at 1:1000 (Alexa Fluor® 488, A-21206, Invitrogen), donkey
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anti-chicken IgG at 1:1000 (Dylight 405, 703-475-155, Jackson
Immunoresearch) and donkey anti-goat IgG at 1:1000 (Cy3, 705-
166-147, Jackson Immunoresearch). Sections were then washed,
once in PBSX, once in PBS and once in PB (saline), mounted onto
slides, and coverslipped using Vectashield mountant. Cerebellar
sections were co-immunostained for DAO and GFAP in the same
way, but the anti-TH antibody was not used.
IN VIVO MICRODIALYSIS AND HIGH PERFORMANCE LIQUID
CHROMATOGRAPHY
In vivo microdialysis, with HPLC detection, was used to mea-
sure extracellular dopamine and its metabolites homovanillic
acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in the
medial frontal cortex of anaesthetized rats following intra-VTA
injection of sodium benzoate, D-serine, the combination, or vehi-
cle. All animal procedures were carried out in accordance with
the UK Animals (Scientific Procedures) Act 1986 and associated
Home Office guidelines, and with local ethical approval.
Adult male Sprague-Dawley rats (Harlan, UK) were anaes-
thetized with chloral hydrate (500mg/kg i.p.) and mounted
in a stereotaxic frame in the flat skull position. Anesthesia
was maintained with supplementary doses of chloral hydrate,
and hydration sustained using 4% glucose in 0.18% saline. A
craniotomy was made using a drill (Foredom®, Bethel, USA)
and a microdialysis probe (crafted in-house) was stereotaxi-
ally implanted into the medial frontal cortex (AP +3.2mm;
ML+0.6mm;DV−5.0mm, relative to bregma and dura; Paxinos
and Watson, 1998). The probe was secured using a cranial screw
(2mm, Royem Scientific, Luton, UK) and Simplex Rapid™ den-
tal cement (Kemdent®, Swindon, UK). The probe was perfused
with artificial cerebrospinal fluid (containing 140.0mM NaCl,
3.0mM KCl, 1.2mM Na2HPO4.2H2O, 0.27mM NaH2PO4.H2O,
1.0mM MgCl2.6H2O, 2.4mM CaCl2, and 7.2mM glucose) con-
taining 3µM nomifensine at a flow rate of 1µl/min. Dialysates
were collected every 20min in Eppendorf tubes containing 5µl
of 0.1M perchloric acid. A guide cannula (26G, 11m length,
PlasticsOne®) was implanted above the VTA (ML + 0.8mm;
AP −5.7mm; DV −6.8mm relative to bregma and dura).
Following a stabilization period of at least 1 h, one of the fol-
lowing solutions was administered into the VTA [0.5µl at a
rate of 90 nl/min via injection needle (33G, PlasticsOne®)]:
200µg/µl sodium benzoate (n = 4); 5mM D-serine (n = 4);
5mM D-serine plus 200µg/µl sodium benzoate (n = 7); or
saline (0.9% NaCl) vehicle (n = 6). Sampling continued for
2 h post-injection, after which pontamine sky blue (0.5µl) was
injected into the VTA for histological determination of injec-
tion site placement. Probe and injection needle placements were
checked histologically.
Dialysate samples (25µl) were analyzed for dopamine,
DOPAC, and HVA, using HPLC with electrochemical detec-
tion. Analytes were separated on a Dynamax microsorb col-
umn (100 × 4.6mm, 100-3 C18, Varian Inc., Middelburg, The
Netherlands) using a mobile phase containing 15% methanol,
0.12M NaH2PO4.H2O, 0.002M NaCl, 0.1mM EDTA, and
0.5mM 1-octanesulphonic acid sodium salt (overall pH 4.17)
at a flow rate of 1ml/min (PU-1585, HPLC Pump, JASCO,
Essex, UK). Assays were calibrated to standard solutions. JASCO
ChromPass Chromatography Data System software (JASCO,
Essex, UK) was used to plot the chromatograms and analyze the
data. Analyte peaks weremeasured and quantified when the signal
to noise ratio exceeded 2.
DATA ANALYSIS
Statistical analyses were carried out with SPSS for Windows 17.
Repeated-measures ANOVAs were performed to assess the effects
of time and drug on dopamine, DOPAC, and HVA relative to
baseline. Simple main effects tests were carried out if the ANOVA
was significant (P < 0.05).
RESULTS
DAO mRNA IS EXPRESSED IN THE VTA
The riboprobe detected a single band of the predicted size of
the rat DAO transcript, ∼2 kilobases (Figure 1A; Konno, 1998).
In situ hybridization histochemistry showed expression of DAO
mRNA in the rat VTA, with clustering over neurons and over the
neuropil (Figure 1B). The latter is likely to reflect DAO mRNA in
un-counterstained glial processes, since sense strand hybridiza-
tion produced minimal background neuropil signal (Figure 1C).
In the cerebellum, grains were concentrated in the Purkinje cell
layer, as anticipated given the known localization of DAO to
Bergmann glia which surround the Purkinje cells (Figure 1D).
Cerebellar non-specific signal was low, as in VTA (Figure 1E).
DAO IMMUNOREACTIVITY IS PRESENT IN THE VTA
Using immunofluorescence histochemistry, DAO immunoreac-
tivity could be seen in VTA neurons and glia (Figure 2A).
Staining was punctate within the cytoplasm, and with an absence
of nuclear labeling. Many DAO-immunoreactive neurons were
also TH-immunopositive; however, not all DAO-positive neurons
were TH-immunopositive, and vice versa. DAO-immunoreactive
GFAP-positive astrocytes were also identified (Figure 2A, insert).
Thus, in VTA, DAO is detectable in some neurons, both dopamin-
ergic and non-dopaminergic, and in glia. No quantification
of immunolabeling was carried out. In the cerebellum, DAO
immunostaining was visible around the periphery of Purkinje
cells (but not over the cell bodies), and also in cell processes pro-
jecting into the molecular layer (Figure 2B), co-localizing with
GFAP immunoreactivity, consistent with the known cerebellar
localization of DAO in Bergmann glia.
EFFECTS OF SODIUM BENZOATE, D-SERINE, AND THE COMBINATION,
ON EXTRACELLULAR DOPAMINE LEVELS IN MEDIAL FRONTAL CORTEX
Sodium benzoate, injected into the VTA, increased extracel-
lular dopamine in the medial frontal cortex [F(1, 7) = 14.559,
p = 0.007], peaking at 40min post-injection [main effect of time:
F(5, 35) = 5.413, p = 0.001; drug × time interaction F(5, 35) =
5.456, p = 0.001; Figure 3A]. Levels of extracellular DOPAC
(Figure 3B) andHVA (Figure 3C) were also elevated after sodium
benzoate, and peaked at 100 and 120min post-injection, respec-
tively [DOPAC: effect of drug F(1, 8) = 8.643, p = 0.019; effect
of time F(5, 40) = 48.919, p < 0.001; drug × time interac-
tion F(5, 40) = 16.775, p < 0.001. HVA: effect of drug F(1, 8) =
11.931, p = 0.009; effect of time F(5, 40) = 37.848, p < 0.001;
drug × time interaction F(5, 40) = 8.625, p < 0.001].
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FIGURE 1 | Expression of DAO mRNA in rat VTA and cerebellum.
(A) Northern blot of rat cerebellar RNA showing that the DAO cRNA
probe detects a single band of ∼2 kb. (B) In situ hybridization, showing
signal for DAO mRNA in the VTA, with clusters of grains over neurons
(arrow). (C) VTA, sense strand hybridization control, showing low level
of background signal. (D) Cerebellum, showing DAO mRNA
concentrated in the Purkinje cell layer (P) with moderate signal in the
granule cell layer (G) and low signal in the molecular layer (M).
(E) Cerebellum, sense strand hybridization control. Sections are
counterstained with cresyl violet.
FIGURE 2 | DAO immunoreactivity in rat VTA and cerebellum. (A)
Triple-labeling in VTA showing immunofluorescence for DAO (green),
tyrosine hydroxylase (TH, blue), and glial fibrillary acidic protein (GFAP,
red). The open head arrows point to two TH-positive neurons
immunoreactive for DAO; the closed head arrows show
DAO-immunoreactive TH-negative neurons. The inset shows a
DAO-immunoreactive GFAP-positive astrocyte. (B) Double-labeling in
cerebellum, showing DAO (green), and GFAP (red) immunoreactivity.
Punctate labeling for DAO is concentrated in the Purkinje cell layer (P),
wherein it surrounds the unlabeled Purkinje cell somata (asterisk), and
the immunoreactivity extends into the molecular layer (M) along
GFAP-positive processes. G: granule cell layer. Bar: 50 microns.
We next investigated whether intra-VTA injection of D-serine
would have the same effect as sodium benzoate. D-serine had no
effect on dopamine levels in medial frontal cortex when com-
pared with vehicle [effect of drug F(1, 7) = 0.223, p = 0.651;
effect of time F(5, 35) = 1.081, p = 0.388; drug× time interaction
F(5, 35) = 0.854, p = 0.521; Figure 3D]. However, D-serine did
increase DOPAC (Figure 3E) and HVA (Figure 3F), both of
which continued to rise throughout the 120min after injec-
tion [DOPAC: effect of drug F(1, 8) = 8.582, p = 0.019; effect
of time F(5, 40) = 30.886, p < 0.001; drug × time interaction
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FIGURE 3 | Dopamine (DA) and its metabolites DOPAC and HVA in
medial frontal cortex (mPFC) after injection of sodium benzoate
(SB), D-serine (DS), the combination (SB+DS), or vehicle (Veh), into
the rat VTA. (A–C) Effects of sodium benzoate, showing increases in
DA (A), DOPAC (B), and HVA (C). (D–F) Effects of D-serine, showing
no effect on DA (D), but increases in DOPAC (E) and HVA (F). (G–I)
Effects of combined sodium benzoate and D-serine, showing increases
in DA (G) and no significant change in DOPAC (H) or HVA (I). The
arrow in each panel denotes the time of injection. ∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.005.
F(5, 40) = 7.006, p < 0.001; HVA: effect of drug F(1, 8) = 22.805,
p = 0.001; effect of time F(5, 40) = 41.256, p < 0.001; drug ×
time interaction F(5, 40) = 8.076, p < 0.001].
Finally, we assessed whether the combination of sodium ben-
zoate and D-serine would show a greater effect than either alone.
Concurrent intra-VTA injection of sodium benzoate and D-
serine increased extracellular dopamine in medial frontal cortex,
peaking 40min post-injection [effect of drug F(1, 10) = 5.504,
p = 0.041; effect of time F(5, 50) = 3.252, p = 0.013; drug × time
interaction F(5, 50) = 3.678, p = 0.007; Figure 3G]. There was an
equivocal effect on DOPAC (Figure 3H), with no main effect of
drug [F(1, 11) = 0.714, p = 0.416], but a significant effect of time
[F(5, 55) = 13.062, p < 0.001], and a drug × time interaction
[F(5, 55) = 3.117, p = 0.015]. HVA was not significantly affected
by the sodium benzoate/D-serine combination (Figure 3I), with
no main effect of drug [F(1, 11) = 1.764, p = 0.211], and no
drug × time interaction [F(5, 55) = 1.081, p = 0.381].
DISCUSSION
Little is known as to the interaction between DAO and the
dopamine system. We investigated the expression and localiza-
tion of DAO in the rat VTA, and carried out a preliminary study
of its functional impact upon the mesocortical dopamine system.
We found that DAOmRNA (Figure 1) and protein (Figure 2) are
present in the VTA, as demonstrated using in situ hybridization
and immunofluorescence, respectively. DAO expression was iden-
tified in three cell types: TH-positive neurons, TH-negative neu-
rons, and GFAP-positive astrocytes. In vivo microdialysis studies
(Figure 3) showed elevated levels of dopamine and its metabo-
lites inmedial frontal cortex after intra-VTA administration of the
DAO inhibitor sodium benzoate. Co-administration of sodium
benzoate with D-serine did not enhance this effect, and D-serine
alone did not alter dopamine but did increase DOPAC and HVA.
These results show the presence of DAO in the VTA, suggest a
physiological role for DAO within VTA in modulating cortical
dopamine, and may have implications for use of DAO inhibitors
in schizophrenia.
EXPRESSION OF DAO IN THE VTA
DAO mRNA and immunoreactivity were both detected in the rat
VTA, extending existing studies which suggested expression of
DAO in the dopaminergic midbrain (Moreno et al., 1999; Verrall
et al., 2007).
DAO is classically considered to be a glial enzyme, and our
findings in the cerebellum are consistent with many previous
studies which show DAO to be enriched primarily in Bergmann
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glia (Weimar and Neims, 1977; Horiike et al., 1987; Verrall
et al., 2007; Ono et al., 2009; Burnet et al., 2011). In the VTA,
DAO was also glial, being seen in some GFAP-immunoreactive
astrocytes. However, we also found DAO mRNA and immunore-
activity in VTA neurons, the latter being TH-positive (presumed
dopaminergic) neurons, as well as some TH-negative neurons.
The presence of neuronal DAO in other brain regions has been
reported in some previous studies (Moreno et al., 1999; Verrall
et al., 2007: Popiolek et al., 2011), and recently in spinal cord (Paul
et al., 2014). In glia, DAO is localized to peroxisomes (Sacchi et al.,
2008), but in neurons it has a broader subcellular distribution and
associates with the presynaptic protein Bassoon, an interaction
which inhibits DAO activity (Popiolek et al., 2011). Whether this
also applies to VTA neurons, and whether this differential subcel-
lular distribution is paralleled by functional differences between
neuronal and glial DAO is unknown. Further studies are also
needed to establish the proportions and neurochemical identi-
ties of DAO-positive cells in the VTA (e.g., using quantitative
immunohistochemistry, and single cell PCR).
INHIBITION OF VTA DAO AFFECTS CORTICAL DOPAMINE
A role for DAO in the VTA cannot be assumed just by virtue of its
expression therein, since DAO mRNA and immunoreactivity are
also detected in frontal cortex (Moreno et al., 1999; Hashimoto
et al., 2007; Verrall et al., 2007), yet there is limited evidence
for functionality of cortical DAO, and cortical D-serine concen-
trations are not elevated in the ddY/DAO− mouse (Yamanaka
et al., 2012). Our in vivo microdialysis data suggest that VTA
DAO is indeed functional (complementing the observations of
Fernandez-Espejo et al., 2008), since local injection of the DAO
inhibitor sodium benzoate increased extracellular dopamine and
its metabolites in medial frontal cortex (Figures 3A–C). The
increase in dopamine was rapid and transient, whereas the ele-
vation in HVA and DOPAC was delayed and longer lasting. This
is in keeping with earlier findings that the response of dopamine
metabolites to stimulation of dopamine neurons is delayed com-
pared to that of dopamine itself (Nakahara et al., 1992); the likely
explanation is that the metabolites arise principally from newly
synthesized dopamine, and that dopamine synthesis is activated
when the firing of the neurons is elevated (Zetterström et al.,
1988).
A plausible mechanism for the observed effect of VTA
sodium benzoate on cortical dopamine is as follows. Sodium
benzoate inhibits local DAO, decreasing D-serine degradation
and thereby increasing extracellular D-serine concentrations; the
increased co-agonist availability enhances NMDAR signaling,
with a resulting increase in dopamine neuron firing and thence
dopamine release. This explanation is consistent with the known
metabolism of D-serine by DAO (Almond et al., 2006; Adage
et al., 2008; Duplantier et al., 2009; Strick et al., 2011), the
effects of D-serine on NMDA receptor function (Schell et al.,
1997; Mothet et al., 2000; Stevens et al., 2003; Panatier et al.,
2006; Fossat et al., 2012; Papouin et al., 2012), and the regula-
tion of dopamine neuron firing and release by NMDA receptors.
That is, activation of VTA NMDA receptors enhances dopamine
neuron burst firing (Seutin et al., 1990; Chergui et al., 1993;
Wang and French, 1993) and stimulates cortical dopamine release
(Kalivas et al., 1989; Takahata and Moghaddam, 1998; Westerink
et al., 1998). Our recent finding that DAO knockout mice show
increased VTA dopamine neuron burst firing when compared
with their wild-type littermates supports this model (Schweimer
et al., in review). The affected population of VTA NMDA recep-
tors likely resides on the dopamine neurons themselves (Petralia
et al., 1994; Standaert et al., 1994), although indirect effects via
NMDA receptors located on non-dopamine VTA neurons, or glia,
cannot be excluded (Steffensen et al., 1998).
However, there are important caveats to this proposed
sequence of events: we did not directly measure VTA DAO activ-
ity, nor levels of D-serine and other NMDA receptor co-agonists,
nor indices of NMDA receptor signaling. As such, any explana-
tion for the effect of sodium benzoate on cortical dopamine based
on alterations in these parameters is speculative. Indeed, regard-
ing the first caveat, the postulated mechanism of effect of DAO
inhibition (via elevation of D-serine availability) is somewhat
at odds with the fact that D-serine had no effect on dopamine
(Figure 3D), and the combination of sodium benzoate plus D-
serine did not elevate cortical dopamine more than sodium ben-
zoate alone (Figures 3G vs. 3A). Moreover, the rise in dopamine
metabolites, especially HVA, was less pronounced after com-
bined sodium benzoate/D-serine injection (Figures 3H,I) than
with either drug alone (Figures 3B,C,E,F), although the differ-
ences were not statistically different. Whilst the results remain
preliminary, given the sample sizes, the findings do together sug-
gest that sodium benzoate may be acting through a mechanism
partly or wholly independent of DAO inhibition. We are not
aware of any such off-target effects being reported (e.g., inhibi-
tion of other enzymes), but the metabolism of sodium benzoate
does interact with availability of glycine, another NMDA receptor
co-agonist (Van Hove et al., 2005), an interaction which may be
relevant in some way. Potential non-DAO-mediated effects could
be tested by (a) direct demonstration of VTADAO inhibition after
sodium benzoate administration using enzyme assay; (b) repli-
cating the present results using additional DAO inhibitors, and
(c) repeating the present study in DAO knockout or ddY/DAO−
mice and showing that cortical dopamine is unaffected by sodium
benzoate.
Assuming that the present findings do result from DAO inhi-
bition, the question remains as to why D-serine administration
did not reproduce or synergize the effect of sodium benzoate
on cortical dopamine. Perhaps DAO inhibition affects a sub-
strate other than D-serine, for example D-alanine, which is a high
affinity NMDA receptor co-agonist (Tanii et al., 1994) metab-
olized by DAO (Molla et al., 2006; Horio et al., 2009), and
whose levels rise markedly in rodents lacking DAO (Yamanaka
et al., 2012). Alternatively, the injected D-serine may be rapidly
removed from the synapse via a transporter (Helboe et al., 2003;
Rutter et al., 2007; Burnet et al., 2008b; Sikka et al., 2010), or
metabolized by serine racemase (Foltyn et al., 2005; Strisovsky
et al., 2005). The fact that D-serine given alone increased the lev-
els of dopamine metabolites (Figures 3E,F) but not dopamine
(Figure 3D) suggests that it had a mild and transient enhanc-
ing effect on dopamine neurons, but that breakdown of the
newly synthesized dopamine resulted in no detectable increase
in dopamine itself (Zetterström et al., 1988). To help distinguish
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between these explanations, it would be valuable to measure
local, extracellular NMDA receptor co-agonist concentrations
after DAO inhibition.
Finally, to confirm that the observed effect of sodium ben-
zoate on cortical dopamine is mediated via enhanced VTANMDA
receptor signaling, electrophysiological measurements of NMDA
receptor currents, and use of selective NMDA receptor antago-
nists would be required. The use of mice with selective inacti-
vation of NMDA receptors on dopamine neurons (Zweifel et al.,
2011; Wang et al., 2011) would also be of interest.
IMPLICATIONS FOR SCHIZOPHRENIA THERAPY
The rationale for DAO inhibitors as a treatment for schizophre-
nia has come from their potential to increase D-serine availability,
thus correcting the postulated NMDA receptor co-agonist defi-
ciency (Marek et al., 2010; Verrall et al., 2010; Labrie et al., 2012).
The case is supported by findings that patients have increased
DAO activity and expression (Kapoor et al., 2006; Verrall et al.,
2007; Burnet et al., 2008a; Madeira et al., 2008), complemented
by equivocal evidence for lower D-serine levels (Hashimoto et al.,
2003; Bendikov et al., 2007; Brouwer et al., 2013) and initial find-
ings that novel DAO inhibitors show efficacy in preclinical models
of schizophrenia (Adage et al., 2008) and, for sodium benzoate, in
the disorder itself (Lane et al., 2013).
All existing licensed drug treatments for schizophrenia are
dopamine D2 receptor antagonists, and the question arises
whether DAO inhibitors may also work, at least partly, via
dopaminergic effects. Our results suggest that this is possible,
but there are several important considerations to bear in mind.
Firstly, systemic administration of the drugs may well give a dif-
ferent result (Bennett and Gronier, 2007; Smith et al., 2009),
since NMDA receptors in frontal cortex and nucleus accum-
bens have differing effects on dopamine release compared to
those located in the midbrain (Imperato et al., 1990; Takahata
and Moghaddam, 1998; Del Arco and Mora, 2001). Indirect
effects could also occur; e.g., inhibition of DAO in the cere-
bellum might impact on the cerebellar regulation of cortical
dopamine (Mittleman et al., 2008; Rogers et al., 2011). Secondly,
it will be important to study chronic as well as acute administra-
tion, and a range of doses. Thirdly, rat DAO has some different
enzymatic properties compared to human DAO (Sacchi et al.,
2013), highlighting the possibility of species differences in the
relationship between DAO and dopamine. Finally, the dopamin-
ergic dysfunction of schizophrenia is complex, with excess striatal
dopamine underlying positive symptoms, and hypofunction of
the mesocortical dopamine projection contributing to cogni-
tive/negative symptoms (Weinberger, 1987; Davis et al., 1991;
Howes and Kapur, 2009; Laruelle, 2013). Simplistically, therefore,
enhancement of cortical dopamine release by DAO inhibition
might be therapeutic for the latter domains, but if a similar
effect occurred in striatum it might exacerbate positive symp-
toms. It is therefore notable that NMDA receptors appear to play
a lesser role in regulation of dopamine in nucleus accumbens
than in frontal cortex (Kalivas et al., 1989; Karreman et al., 1996;
Doherty and Gratton, 1997; Westerink et al., 1998; Mathe et al.,
1999), providing the possibility that DAO inhibition might be
able to enhance cortical dopamine function without significantly
increasing striatal dopamine. This speculation remains to be
empirically tested.
In summary, we show that DAO is present in neurons and
glia of the rat VTA, and provide preliminary evidence that VTA
DAO influences the mesocortical dopamine system, since injec-
tion of a DAO inhibitor into the VTA increased dopamine in the
frontal cortex. As well as replication of the current findings, con-
siderable further study is required to extend them and to clarify
the underlying mechanisms. Nevertheless, the present findings
draw attention to the possible interaction between DAO and the
dopamine system, which has potential relevance for the ongoing
development of DAO inhibitors to treat schizophrenia and other
disorders.
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